| Browse All

PharmaCyte Biotech, Inc. (PMCB)

Healthcare | Biotechnology | Las Vegas, United States | NasdaqCM
0.76 USD +0.04 (5.905%) ⇧ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★★☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:30 a.m. EDT

PMCB is a high-beta biotech stock currently trading at a deep discount (-17% below 200-day MA) funded by successful Femasys stakes monetization and equity raises. The fundamental picture is neutral-to-negative (-EPS, high debt-to-cash risk), but the short-term catalyst seems to be late-stage speculation at the $2.50 level. This disconnect suggests the market is waiting for either a clinical breakthrough or a short squeeze, making it a poor neutral hold but a volatile, asymmetric opportunity for aggressive traders, not a long-term buy-and-hold vehicle given the lack of dividends and negative earnings.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.168359
AutoETS0.173759
AutoARIMA0.177011
MSTL0.193359

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 40%
H-stat 1.80
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 1.09
Attribute Value
Sector Healthcare
Market Cap 8,202,036
Forward P/E -2.01
Beta 0.41
Website https://pharmacyte.com

As of April 19, 2026, 12:30 a.m. EDT: Call volume and Open Interest are heavily skewed toward the $2.50 strike (a massive moon shot), indicating speculative leverage rather than a near-term directional bet. In contrast, $1.00 shows significant Open Interest with zero Implied Volatility, suggesting a potential anchor or insurance level, while the $0.50 strike is the only listed ATM anchor despite slightly negative positioning changes. The disparity between deep OTM speculation ($2.50) and the lack of a $0.50 wing suggests a market split between extreme asymmetry plays and avoiding a defined downside.


Info Dump

Attribute Value
52 Week Change -0.3327511
Address1 3,960 Howard Hughes Parkway
Address2 Suite 500
All Time High 961.0
All Time Low 0.63
Ask 0.77
Ask Size 1
Average Daily Volume10 Day 136,870
Average Daily Volume3 Month 182,814
Average Volume 182,814
Average Volume10Days 136,870
Beta 0.409
Bid 0.7395
Bid Size 1
Book Value 3.589
City Las Vegas
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.764
Current Ratio 12.332
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 0.7739
Day Low 0.705
Display Name PharmaCyte Biotech
Earnings Timestamp End 1,755,288,000
Earnings Timestamp Start 1,754,942,400
Ebitda Margins 0.0
Enterprise Value -11,463,427
Eps Forward -0.38
Eps Trailing Twelve Months -0.89
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 917 595 2851
Fifty Day Average 0.705186
Fifty Day Average Change 0.05881399
Fifty Day Average Change Percent 0.08340209
Fifty Two Week Change Percent -33.27511
Fifty Two Week High 1.51
Fifty Two Week High Change -0.746
Fifty Two Week High Change Percent -0.49403974
Fifty Two Week Low 0.63
Fifty Two Week Low Change 0.134
Fifty Two Week Low Change Percent 0.21269841
Fifty Two Week Range 0.63 - 1.51
Financial Currency USD
First Trade Date Milliseconds 1,357,137,000,000
Float Shares 9,960,106
Forward Eps -0.38
Forward P E -2.0105264
Free Cashflow -1,694,738
Full Exchange Name NasdaqCM
Full Time Employees 2
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.057439998
Held Percent Institutions 0.091680005
Implied Shares Outstanding 10,735,649
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-08-10
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,745,971,200
Last Split Date 1,626,048,000
Last Split Factor 1:1550
Long Business Summary PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Long Name PharmaCyte Biotech, Inc.
Market us_market
Market Cap 8,202,036
Market State PRE
Max Age 86,400
Message Board Id finmb_3563709
Most Recent Quarter 1,769,817,600
Net Income To Common -7,486,426
Next Fiscal Year End 1,777,507,200
Non Diluted Market Cap 8,202,035
Open 0.705
Operating Cashflow -4,800,723
Operating Margins 0.0
Payout Ratio 0.0
Phone 917 595 2850
Previous Close 0.7214
Price Hint 4
Price To Book 0.21287267
Profit Margins 0.0
Quick Ratio 12.238
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.042599976
Regular Market Change Percent 5.905181
Regular Market Day High 0.7739
Regular Market Day Low 0.705
Regular Market Day Range 0.705 - 0.7739
Regular Market Open 0.705
Regular Market Previous Close 0.7214
Regular Market Price 0.764
Regular Market Time 1,776,715,200
Regular Market Volume 168,755
Return On Assets -0.06751
Return On Equity -0.082399994
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 10,735,649
Shares Percent Shares Out 0.0091
Shares Short 97,390
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 106,373
Short Name PharmaCyte Biotech, Inc.
Short Percent Of Float 0.0095999995
Short Ratio 0.62
Source Interval 15
State NV
Symbol PMCB
Total Cash 20,537,786
Total Cash Per Share 1.913
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.89
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.8744755
Two Hundred Day Average Change -0.11047548
Two Hundred Day Average Change Percent -0.12633342
Type Disp Equity
Volume 168,755
Website https://pharmacyte.com
Zip 89,169